Compare Abeona Therapeutics Inc (ABEO) vs Alphabet Inc Class A (GOOGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Alphabet Inc Class A — how do they compare? Abeona Therapeutics Inc trades at $7.5 (market cap $421.19M), while Alphabet Inc Class A trades at $343.87 (market cap $4.20T). The key difference: Alphabet Inc Class A is far larger — about 9971.7× Abeona Therapeutics Inc's market cap, and Alphabet Inc Class A pays a 0.26% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | GOOGL | |
|---|---|---|
Market Cap | $421.19M | $4.20T |
Sector | Health | Media |
52-Week High | $7.45 | $402.62 |
52-Week Low | $4.17 | $199.32 |
Enterprise Value | $276.10M | $4.09T |
Dividend Yield | — | 0.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.40, down 0.67% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 2026 results with revenue growth and beat EPS estimates for three consecutive quarters. Recent news includes CMS granting NTAP status for ZEVASKYN and expansion of its treatment center network, indicating positive commercial momentum.
Outlook is supported by analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high P/S ratio, negative operating cash flow, and a shareholder investigation. The stock's valuation remains attractive on P/E and EV/EBITDA bases, though execution on revenue growth is critical for sustained upside.
Alphabet (GOOGL) trades at $344.00, down 3.78% on the day, with technical indicators showing bearish momentum below key resistance at $347. Fundamentally, the company demonstrates strong profitability with 54.77% net income margin and consistent earnings beats, though valuation multiples remain elevated with P/E at 17.25. Recent developments include YouTube subscription price increases and continued AI infrastructure investments.
The stock presents a compelling long-term opportunity given strong analyst consensus (85% buy ratings) and $426.28 price target, representing 24% upside. Key risks include antitrust scrutiny and tech sector rotation pressures, but Alphabet's AI leadership and diversified revenue streams support growth prospects despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →
